Welcome to our dedicated page for ARTELO BIOSCIENCES SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artelo Biosciences, Inc. filings document a clinical-stage pharmaceutical issuer with securities listed on Nasdaq and a pipeline centered on lipid-signaling modulation. Registration statements and amendments describe securities offerings, delayed or continuous offering registration mechanics, common stock, warrants, pre-funded warrants and capital-structure terms.
Artelo's Form 8-K filings record material events including Nasdaq continued-listing compliance, annual-meeting matters, private-placement activity, material agreements, and clinical or regulatory disclosures for programs such as ART27.13 and ART26.12. The filings connect formal governance and financing records with updates on the company's drug-development strategy and intellectual-property activity.
Artelo Biosciences director Gregory Reyes received a small stock option grant. On January 30, 2026, he was awarded options to buy 292 shares of Artelo Biosciences common stock at an exercise price of $1.71 per share, held directly. These options vest 100% on the earlier of January 30, 2027 or the day before the next annual shareholder meeting, as long as he continues serving the company.
ARTELO BIOSCIENCES, INC. reported that its Chief Financial Officer, Mark Edward Spring, received a grant of stock options on January 29, 2026. The grant covers 36,391 stock options with an exercise price of $1.68 per share.
These options vest over four years, starting from a vesting commencement date of January 1, 2026. One forty-eighth of the option shares vests each month, so the award becomes fully vested on the four-year anniversary of that commencement date, as long as he continues as a service provider.
Artelo Biosciences reported a Form 4 insider transaction for President, CEO, CFO, Treasurer and Secretary Gregory D. Gorgas. He was granted 154,713 stock options on January 29, 2026 with an exercise price of $1.68 per share and expiration on January 29, 2036.
These options vest in equal monthly installments, with 1/48 of the shares vesting each month starting from a vesting commencement date of January 1, 2026, so long as he continues as a service provider. The entire grant is scheduled to be fully vested after four years.
Artelo Biosciences, Inc. reconvened its Annual Meeting of Stockholders on January 30, 2026 and reported the voting results. The meeting had previously been convened on December 31, 2025 and adjourned because there were not enough shares represented to form a quorum.
Of the 2,018,746 shares of common stock outstanding as of the December 10, 2025 record date, 1,017,816 shares were represented at the reconvened meeting, or approximately 50.4% of the shares entitled to vote. Stockholders cast votes on the election of two director nominees and on two additional matters, with detailed tallies provided for each item.
Artelo Biosciences, Inc. received a Nasdaq notice on January 14, 2026 stating it is not in compliance with Nasdaq Listing Rule 5620(a, the annual meeting rule, because its 2025 annual meeting was convened on December 31, 2025 but adjourned for lack of quorum and is scheduled to reconvene on January 30, 2026. Nasdaq indicated this annual meeting deficiency could serve as an additional basis for delisting.
The company has already presented to a Nasdaq Hearing Panel a plan to regain and maintain compliance with the previously disclosed deficiency in the $2.5 million minimum stockholders’ equity requirement under Listing Rule 5550(b)(1. Artelo’s common stock continues to trade on Nasdaq during the hearings process and any extension period, but there is no assurance it will regain full compliance or that its appeal of the earlier equity-based delisting determination will succeed.
Artelo Biosciences, Inc. reported that Nasdaq has issued a determination to delist its common stock after the company failed to regain compliance with Nasdaq Listing Rule 5550(b)(1), which requires stockholders’ equity of at least $2,500,000. Artelo had submitted plans to Nasdaq on July 7, 2025 and August 29, 2025 that relied on raising additional capital, but the expected capital raise has not been completed.
On November 19, 2025, Nasdaq staff notified Artelo that, unless the company requests a hearing by November 26, 2025, its securities will be delisted on December 1, 2025. Artelo intends to appeal this determination to a Nasdaq hearing panel under the Listing Rule 5800 Series, which would stay further delisting actions during the appeal or any extension. The company’s common stock is expected to continue trading on Nasdaq under the symbol ARTL while the appeal process is pending.
Artelo Biosciences, Inc. (ARTL) reported the equity holdings of its Chief Financial Officer in a beneficial ownership statement. The filing lists two stock options to buy common stock, each with an exercise price of $11.03 per share. One option covers 5,000 shares of common stock and vests in equal monthly installments over four years starting from a vesting commencement date of January 1, 2025. The other option covers 2,500 shares of common stock, with half vesting on January 1, 2026 and the remaining half vesting on January 1, 2027, in each case contingent on continued service.
Artelo Biosciences, Inc. is registering up to 899,972 shares of common stock for resale by existing securityholders. These shares consist of 215,292 shares issuable upon conversion of convertible notes, 246,498 shares issuable upon exercise of warrants with a $6.24 exercise price, and 438,182 shares issuable upon exercise of warrants with a $3.40 exercise price. Artelo will not receive proceeds from the resale of these shares, but could receive approximately $3.0 million if all 684,680 warrant shares are exercised for cash. As of November 10, 2025, 2,018,746 shares of common stock were outstanding.
The company highlights significant risks, including substantial doubt about its ability to continue as a going concern, driven by cash of about $1.7 million, negative working capital of about $3.0 million, and a net loss of about $8.7 million for the nine months ended September 30, 2025. Artelo has received a Nasdaq notice for falling below the minimum stockholders’ equity requirement, and large potential resales under this prospectus could put additional pressure on the share price. The company also discloses volatility and liquidity risks tied to a $250,000 investment in the Solana cryptocurrency.
Artelo Biosciences (ARTL) filed its Q3 2025 10‑Q, highlighting liquidity pressure and continued R&D spend. The company reported a net loss of $8.7 million for the nine months ended September 30, 2025, driven by operating expenses of $8.6 million. Cash and cash equivalents were $1.7 million as of September 30, 2025, and management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing.
To fund operations, Artelo executed multiple capital raises: $0.9 million in unsecured convertible notes on May 1; a June private placement with $1.4 million gross proceeds; an at‑the‑market program that sold 50,858 shares for $442,000 net in Q3; and a September underwritten offering with ~$3.0 million gross ($2.87 million net). Subsequent events include an October 1 underwritten offering of ~$2.0 million gross and an October 28 note/warrant financing of $690,000 in notes plus 438,182 warrants at $3.40. Shares outstanding were 2,018,746 as of November 10, 2025. The company also held $325,000 fair value of SOL digital assets (cost $250,000), which flows through earnings under ASU 2023‑08.
Artelo Biosciences entered into a Subscription Agreement and completed a private financing on October 28, 2025, issuing convertible notes totaling $690,154.69 and warrants for 438,182 common shares at $3.40. Investors acquired these securities by converting amounts due at maturity under notes issued on May 1, 2025.
The notes carry 12% annual interest (increasing to 20% upon an Event of Default), mature six months after closing, and are convertible at $3.40 before maturity. The warrants are immediately exercisable for five years, with cash or cashless exercise if no effective resale registration is available, and include standard anti-dilution protections.
Artelo agreed to file a resale registration statement within 20 calendar days of closing and keep it effective until Rule 144 conditions are met. A 4.9% beneficial ownership cap applies, adjustable at a holder’s election up to 19.9%. Directors participated, including Connie Matsui $110,842.52 and 70,376 warrant shares, and Gregory Gorgas $27,710.36 and 17,592 warrant shares.